Stocknear Logo Stocknear
/
Popular
  • KO Coca Cola Company Stock
  • TSLA Tesla Inc Stock
  • AMD Advanced Micro Devices Stock
  • SPY SPDR S&P 500 ETF Trust ETF
  • NVDA Nvidia Stock
    • Login

    Humacyte Inc.

    NASDAQ: HUMA · Real-Time Price · USD
    1.92
    0.04 (2.13%)
    At close: Aug 15, 2025, 9:57 AM
    2.13%
    Bid 1.91
    Market Cap 303.28M
    Revenue (ttm) 7.75M
    Net Income (ttm) -77.67M
    EPS (ttm) -0.47
    PE Ratio (ttm) -4.07
    Forward PE -9.94
    Analyst Buy
    Ask 1.92
    Volume 832,097
    Avg. Volume (20D) 4,688,291
    Open 1.90
    Previous Close 1.88
    Day's Range 1.88 - 1.93
    52-Week Range 1.15 - 7.48
    Beta 1.90

    About HUMA

    undefined

    [Read more]
    Industry n/a
    Sector n/a
    IPO Date n/a
    Employees NaN
    Stock Exchange n/a
    Ticker Symbol HUMA
    Website n/a
    Full Company Profile

    Analyst Forecast

    According to 0 analyst ratings, the average rating for HUMA stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.

    Stock Forecasts

    Next Earnings Release

    Humacyte Inc. is scheduled to release its earnings on Nov 7, 2025, before market opens.
    Analysts project revenue of ... Unlock content with Pro Subscription
    4 days ago
    -29.44%
    Humacyte shares are trading lower after the compan... Unlock content with Pro Subscription
    3 weeks ago
    +18.7%
    Humacyte shares are trading higher after the company announced the first Symvess sale to a U.S. military treatment facility.
    news image

    3 days ago · seekingalpha.com

    Humacyte: Cash Burn And A Glacial Launch Overshadow VAC Progress

    I maintain my Sell rating on Humacyte due to slow SYMVESS adoption, missed Q2 estimates, and ongoing operational challenges. SYMVESS's limited market, negative publicity, and CMS reimbursement hurdles...

    news image

    3 days ago · seekingalpha.com

    Humacyte, Inc. (HUMA) Q2 2025 Earnings Call Transcript

    Humacyte, Inc. (NASDAQ:HUMA ) Q2 2025 Earnings Call August 11, 2025 8:00 AM ET Company Participants Dale A. Sander - CFO, Chief Corporate Development Officer & Treasurer Laura E.

    news image

    3 days ago · zacks.com

    Humacyte, Inc. (HUMA) Reports Q2 Loss, Misses Revenue Estimates

    Humacyte, Inc. (HUMA) came out with a quarterly loss of $0.24 per share versus the Zacks Consensus Estimate of a loss of $0.15. This compares to a loss of $0.27 per share a year ago.

    news image

    1 week ago · zacks.com

    Humacyte, Inc. (HUMA) Stock Dips While Market Gains: Key Facts

    Humacyte, Inc. (HUMA) concluded the recent trading session at $2.21, signifying a -4.33% move from its prior day's close.

    news image

    2 weeks ago · zacks.com

    Humacyte, Inc. (HUMA) Suffers a Larger Drop Than the General Market: Key Insights

    Humacyte, Inc. (HUMA) closed at $2.4 in the latest trading session, marking a -1.23% move from the prior day.

    news image

    3 weeks ago · zacks.com

    Humacyte, Inc. (HUMA) Stock Falls Amid Market Uptick: What Investors Need to Know

    Humacyte, Inc. (HUMA) closed at $2.67 in the latest trading session, marking a -2.2% move from the prior day.

    news image

    1 month ago · zacks.com

    Why Humacyte, Inc. (HUMA) Dipped More Than Broader Market Today

    Humacyte, Inc. (HUMA) closed at $2.28 in the latest trading session, marking a -7.69% move from the prior day.

    news image

    1 month ago · zacks.com

    Humacyte, Inc. (HUMA) Stock Declines While Market Improves: Some Information for Investors

    The latest trading day saw Humacyte, Inc. (HUMA) settling at $2.54, representing a -1.17% change from its previous close.

    news image

    2 months ago · seekingalpha.com

    Humacyte: Revenue Ramp From Symvess Incoming

    Humacyte's Symvess offers a significant clinical advance in vascular trauma, with strong efficacy and cost benefits over synthetic grafts and autologous vein grafts. The company targets a $200M-$480M ...

    news image

    2 months ago · zacks.com

    Is Humacyte, Inc. (HUMA) a Buy as Wall Street Analysts Look Optimistic?

    Investors often turn to recommendations made by Wall Street analysts before making a Buy, Sell, or Hold decision about a stock. While media reports about rating changes by these brokerage-firm employe...

    Add to Watchlist